Patient & Survivor Care
WASHINGTON – FMT shows promise for the treatment of refractory immune checkpoint inhibitor–associated colitis.
Pegfilgrastim-cbqv, previously known as CHS-1701, will be marketed as Udenyca by Coherus BioSciences.
From the Journals
Corticosteroid use was most strongly associated with chemotherapy-induced febrile neutropenia.
Once a patient hears “cancer,” they often stop listening. We could go on, spelling out the next steps and treatment options. But patients usually...
The latest guideline revision aims to establish a foundation for “gold-standard” palliative care.
From the Editor
Without certainty, how can a physician debunk a superstition?